Skip to main content
Skip to footer
Home
News Channels
All News
Reports
Press Room
Contact Us
About Us
All Categories
Antibodies
DNA RNA and Cells
More News
Proteins and Peptides
Small Molecules
Vaccines
Any Word
All Words
Exact Phrase
CAR T-Cells
Jul 2022
Claudin 6, Cadherin 17, ROR1 and GPRC5D-Targeted Therapies: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis
2.550,00€
1.800,00€
Jul 2022
GPRC5D-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis
600,00€
May 2022
Cadherin 17: A target opportunity to develop effector-enhanced drug modalities
400,00€
May 2022
Claudin 6: A target opportunity to develop effector-enhanced drug modalities
500,00€
←
1
2
Any Word
All Words
Exact Phrase
Report categories
Antibody & Protein Sales
Antibody Technologies
Biosimilar Antibodies & Proteins
CAR T-Cells
Drug the Undruggable Technologies
Immuno-Oncology
mRNA Vaccines & Therapeutics
NK Cells & CAR Macrophages
Pipeline Database
RNA-Targeted Therapeutics
Target Pipelines
TCR T-Cells and Antibodies
Therapeutic Antibodies
Therapeutic Proteins & Peptides
